Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Conatus Pharmaceuticals Inc.
• Collaborator: Idun Pharmaceuticals
• Treatments: Caspase Inhibitors

Criteria

Inclusion Criteria:

• Minimum adult age

Exclusion Criteria:

• Fulminant hepatic failure (UNOS Status I patients)

• Previous liver transplantation

• Patients undergoing split liver grafts

• Extrahepatic malignancy

• If female, pregnant or lactating